Scroll To Top
Issue Features

In the Pipeline

In the Pipeline


Although no major medications are expected to hit the market in the next few months, the drug pipeline does contain a handful of candidates that are reaching the research stage of final clinical trials. ENTRY INHIBITORS [Medication Name/Code (with Drug Class), Research Stage, Manufacturer] ' DP-178 (fusion inhibitor), Preclinical, Weizmann Institute ' GP41 inhibitor, Preclinical, Locus Pharmaceuticals ' GSK706769 (CCR5 blocker), Phase I, GlaxoSmithKline ' IC9564 (BA entry inhibitor), Preclinical, Duke University ' INCB15050 (CCR5 blocker), Phase I, Incyte ' MDX-010 (CTLA-4 blocker), Preclinical, Medarex ' PF232798 (CCR5 blocker), Phase II, Pfizer ' PRO-140 (monoclonal antibody), Phase II, Progenics ' Sifuvirtide (fusion inhibitor), Phase IIb, FusoGen ' TBR-220 (CCR5 blocker), Phase I, Tobira ' TBR-652 (CCR5 blocker), Phase I, Tobira ' Ibalizumab TNX-355 (monoclonal antibody), Phase II, Taimed ' TRI-1144 (fusion inhibitor), Preclinical, Trimeris and Roche ' Vicriviroc (CCR5 blocker), Phase III, Schering-Plough ' Zinc finger protein nucleases (CCR5 blockers), Preclinical, Sangamo Biosciences -------------------- INTEGRASE INHIBITORS [Medication Name/Code, Research Stage, Manufacturer] ' Beta-diketo acids, Preclinical, University of Parma and University of Sassari ' Elvitegravir (GS-9137), Phase III, Gilead Sciences ' GS-9224, Preclinical, Gilead Sciences ' GSK364735, Phase I, GlaxoSmithKline/Shionogi ' GSK13495172, Phase II, GlaxoSmithKline -------------------- MATURATION INHIBITORS [Medication Name/Code, Research Stage, Manufacturer] ' Betulinic acid derivatives, Preclinical, University of North Carolina, Duke University, Vanderbilt University ' Bevirimat (gag processing inhibitor), Phase II, Myriad ' Capsid inhibitors, Preclinical, Achillion ' MPC 9055, Phase II, Myriad ' PA1050040, (gag processing inhibitor), Phase I, Panacos ' RPI-MN, (nAchR receptor inhibitor), Preclinical, ReceptoPharm -------------------- NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS [Medication Name/Code, Research Stage, Manufacturer] ' C-8 quinolinyloxyethyl substitutent, Preclinical, Boehringer Ingelheim ' HBY097 (Pyridinone derivatives), Preclinical, Rutgers University ' IDX899, Phase II, Idenix/GSK ' MV026048, Preclinical, Medivir ' Oligodeoxynucleotides, Preclinical, University of Zurich ' Rilpivirine (TMC-278), Phase III, Tibotec ' RDEA806, Phase IIa, Ardea ' RDEA427, Phase I, Ardea ' RDEA640, Preclinical, Ardea ' Thiazole derivatives, Preclinical, Japan's Institute for Virus Research ' UK-435061, Phase II, Pfizer -------------------- NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS [Medication Name/Code, Research Stage, Manufacturer] ' 4-Ed4T, Preclinical, Kagoshima University ' Amdoxovir (DAPD), Phase II, RFS Pharma ' Apricitabine (ATC), Phase IIb/III, Avexa ' Dexelvucitabine (DFC, formerly Reverset), Phase II, Pharmasset ' DOT (dioxolane thymidine), Phase I, University of Georgia ' Elvucitabine (ACH-126), Phase II, Achillion ' Fosalvudine (alovudine prodrug), Phase II, Heidelberg Pharmaceuticals ' GS-9131, Preclinical, Gilead Sciences ' GS-9148, Preclinical, Gilead Sciences ' IDX12899, Preclinical, Idenix Pharmaceuticals ' IDX12989, Preclinical, Idenix Pharmaceuticals ' Quinolones, Preclinical, Rega Institute ' Racivir, Phase II, Pharmasset ' Thiovir, Preclinical, Adventrx ' TSAO-T derivatives, Preclinical, University of Pittsburgh -------------------- PK BOOSTERS [Medication Name/Code, Research Stage, Manufacturer] ' GS-9350, Phase I, Gilead Sciences ' SPI-452, Phase I, Sequoia ' TMC558445, Phase I, Tibotec Pharmaceuticals ' PF-03716539, Phase I, Pfizer -------------------- PROTEASE INHIBITORS [Medication Name/Code, Research Stage, Manufacturer] ' GRL-02031, Preclinical, Kumamoto University ' SPI-256, Phase I, Sequoia -------------------- OTHER CLASSES [Medication Name/Code (with Drug Class), Research Stage, Manufacturer] ' 1H4 (tat inhibitor), Preclinical, Taras Shevchenko University ' BIT225 (Vpu ion blockers), Phase 1, Biotron Limited ' Histone deacetylase inhibitors, Phase I/II, University of California, San Francisco ' HRG214 (caprine IgG), Preclinical, Vironex ' KP-1461 (viral decay accelerator), Phase II, Koronis ' LEDGF (integrase competers), Preclinical, Catholic University of Leuven ' Poly acrylic acid, Preclinical, Chinese Academy of Science ' RSC-1838, Preclinical, GlaxoSmithKline and Shionogi ' SCY-635 (cyclophilin inhibitor), Phase Ib, Scynexis ' siRNA constructs (rev/tat inhibitors), Preclinical, Beckman Institute ' siRNA, Preclinical, CombiMatrix

Out Magazine - Fellow TravelersAdvocateChannel promotion

From our Sponsors

Most Popular

Latest Stories